# Paratus Sciences

> Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.

- **Founded:** 2023
- **Headquarters:** New York, NY, United States (with a site in Singapore)
- **Founders:** Paul Matsudaira (Scientific Co-Founder), Richard Young (Scientific Co-Founder), Thomas Zwaka (Scientific Co-Founder), Amir Nashat (Founding CEO, now Board Chair (Polaris Partners))
- **Team size:** Approximately 20-50 employees across New York and Singapore
- **Products:** Evolutionary discovery platform, PS-1001, Cardiometabolic programs, Bat Biology Foundation
- **Notable:** Launched in 2023 with a $100M Series A from a top-tier investor syndicate, Built one of the largest collections of bat genomes and tissue samples via the Bat Biology Foundation, Advanced PS-1001, a first-in-class pan-inflammasome inhibitor, into its pipeline

## Products & services

- **Evolutionary discovery platform** — An integrated platform combining cell biology, comparative genomics and informatics to compare disease-resistance patterns in bats with disease progression in humans, surfacing novel, evolutionarily validated drug targets.
- **PS-1001** — Lead candidate: a first-in-class pan-inflammasome inhibitor targeting ASC, designed both to prevent new inflammasome assembly and dismantle existing extracellular complexes.
- **Cardiometabolic programs** — Preclinical programs targeting metabolic dysfunction and cellular stress, informed by bat metabolism and heart resilience.
- **Bat Biology Foundation** — A unit advancing bat research by facilitating sample collection from novel bat species and building one of the largest collections of bat genomes and tissue samples.

## Achievements

- Launched in 2023 with a $100M Series A from a top-tier investor syndicate
- Built one of the largest collections of bat genomes and tissue samples via the Bat Biology Foundation
- Advanced PS-1001, a first-in-class pan-inflammasome inhibitor, into its pipeline
- Established a dual-continent footprint in New York and Singapore
- Partnered with National Heart Centre Singapore on bat heart-resilience research
- Appointed veteran biotech CEO Alicia Secor to lead its next growth phase (2026)

## Latest updates

- **2026-04** — Appointed Alicia Secor as President & CEO and expanded the leadership team (CFO Jeffrey Young, Head of Clinical Development Ganesh Mugundu, Senior Medical Advisor Richard Polisson).
- **2024-09** — Announced research partnership with National Heart Centre Singapore on bat heart resilience and heart failure.
- **2024-02** — Presented at the 3rd BioCentury-BayHelix East-West Biopharma Summit.
- **2023-03** — Emerged from stealth with a $100M Series A financing.

## Links

- Website: https://paratussciences.com
- LinkedIn: https://www.linkedin.com/company/paratus-sciences

---

Profile page: https://yespress.io/paratus-sciences
Published by YesPress — https://yespress.io
Last updated: 2026-07-18